Unicycive Therapeutics Class Action Lawsuit Update
The Gross Law Firm has important information for investors concerning Unicycive Therapeutics, Inc. (NASDAQ: UNCY), focusing on a current class action lawsuit. Shareholders who acquired UNCY shares within the specified class period are strongly encouraged to reach out to the firm for possible lead plaintiff considerations. It’s crucial to understand that being appointed as a lead plaintiff is not a prerequisite for taking part in any potential recovery.
Details for Shareholders
This class action involves shareholders who purchased shares from March 29, 2024, to June 27, 2025. If you bought your shares during this time frame, now is the time to consider your options.
Class Period and Allegations
The lawsuit alleges significant misstatements and omissions from the company during this class period. Specifically, it contends that Unicycive overstated its readiness to meet the FDA’s manufacturing compliance requirements and misrepresented the regulatory prospects of its oxylanthanum carbonate new drug application. This lack of transparency has purportedly rendered Defendants’ public statements materially false and misleading.
Deadline for Registration
The critical date for shareholders to take action is October 14, 2025. It’s advisable for anyone interested in participating in the class action to register promptly to ensure they don’t miss out on any potential claims. You may register your information through the designated form.
Next Steps for Involved Shareholders
Upon registration as a shareholder who purchased shares of UNCY within the outlined period, individuals will be integrated into a portfolio monitoring system. This system will keep you updated on the status throughout the litigation process. Again, the October 14, 2025 deadline for seeking lead plaintiff status is significant, but no costs or obligations are attached to your participation.
Why Choose Gross Law Firm?
The Gross Law Firm stands out as a nationally recognized law firm committed to safeguarding the rights of investors affected by fraudulent and deceitful practices. Our aim is to hold companies accountable, ensuring adherence to responsible business operations. The firm is dedicated to pursuing recovery for investors experiencing losses due to misleading statements that artificially inflate stock prices. It’s essential to note that prior outcomes do not guarantee similar future results.
Contact Information for Support
If you have questions or need more details about the class action, please reach out to The Gross Law Firm located at 15 West 38th Street, 12th floor, New York, NY 10018. You can also call (646) 453-8903 for assistance. Email communication is welcome, although the email address is omitted here for security reasons.
Frequently Asked Questions
What is the class period for the Unicycive Therapeutics lawsuit?
The class period is from March 29, 2024, to June 27, 2025.
How can I register for the class action lawsuit?
Shareholders can register by submitting their information through the specified online form.
Is there a cost to participate in the class action?
No, there is no cost or obligation to participate in the class action.
What are the allegations against Unicycive Therapeutics?
The allegations primarily relate to misleading statements regarding the company's compliance with FDA regulations and the prospects of its new drug application.
Who can be a lead plaintiff in the class action?
Any shareholder who purchased shares during the class period can seek to be a lead plaintiff, but it is not necessary to participate in the case.
